# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 03-14-2024 | 12-31-2023 | 10-K | |
2 | 11-09-2023 | 09-30-2023 | 10-Q | |
3 | 08-03-2023 | 06-30-2023 | 10-Q | |
4 | 05-09-2023 | 03-31-2023 | 10-Q | |
5 | 03-15-2023 | 12-31-2022 | 10-K |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Maxim Group analyst Naz Rahman maintains Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy and lowers the price target from $15...
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(2.08) per share which beat the analyst consensus estimate of...
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday. The Dow traded do...
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expect...